Picolinafen

Synonyms: 氟吡酰草胺; AC 900001
Picolinafen 是一种抑制八氢番茄红素去饱和酶 (PDS) 的吡啶类除草剂,可控制阔叶杂草生长并干扰类胡萝卜素生物合成,对猪胚胎滋养外胚层细胞 (pTr) 和子宫腔上皮细胞 (pLE) 具有细胞毒性,可通过诱导 ROS 积累、钙耗竭,激活 MAPK 和 PI3K 信号通路,导致细胞活力下降、凋亡 (apoptosis) 增加、迁移能力受损以及着床相关基因表达改变,其对哺乳动物的 LD50 值为 2.7 mg/kg,对鱼类为 7 μg/L,并在斑马鱼胚胎发育过程中表现出毒性效应。
产品编号: MS-T05190 CAS No.: 137641-05-5 分子式: C19H12F4N2O2 分子量: 376.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Picolinafen 是一种抑制八氢番茄红素去饱和酶 (PDS) 的吡啶类除草剂,可控制阔叶杂草生长并干扰类胡萝卜素生物合成,对猪胚胎滋养外胚层细胞 (pTr) 和子宫腔上皮细胞 (pLE) 具有细胞毒性,可通过诱导 ROS 积累、钙耗竭,激活 MAPK 和 PI3K 信号通路,导致细胞活力下降、凋亡 (apoptosis) 增加、迁移能力受损以及着床相关基因表达改变,其对哺乳动物的 LD50 值为 2.7 mg/kg,对鱼类为 7 μg/L,并在斑马鱼胚胎发育过程中表现出毒性效应。

生物实验数据

生物活性 Picolinafen is a pyridine herbicide that inhibits phytoene desaturase (PDS), controls broadleaf weed growth, and interferes with carotenoid biosynthesis; it is cytotoxic to porcine trophectoderm cells (pTr) and porcine luminal epithelial cells (pLE), and by inducing ROS accumulation and calcium depletion and activating the MAPK and PI3K signaling pathways, it leads to decreased cell viability, increased apoptosis, impaired migration, and altered expression of implantation-related genes, with an LD50 of 2.7 mg/kg in mammals and 7 μg/L in fish, and it exhibits toxic effects during zebrafish embryonic development.
体外研究
(In Vitro)

Picolinafen (0.2-6 μM, 48 h) 降低猪胚胎滋养外胚层细胞 (pTr) 和子宫腔上皮细胞 (pLE) 的细胞活力并改变细胞周期进程。

Picolinafen (1-4 μM, 48 h) 诱导 pTr 和 pLE 细胞凋亡,破坏细胞球体的自我组装能力,并且干扰 pTr 和 pLE 细胞的线粒体完整性和钙稳态。

Picolinafen (1-4 μM, 2-48 h) 导致 pTr 和 pLE 细胞中 ROS 积累并破坏细胞内 Ca2+ 调控。

Picolinafen (4 μM, 15-24 h) 抑制 pTr 细胞迁移并改变与凋亡和着床相关基因的转录调控。

Picolinafen (1-4 μM, 3 h) 激活 pTr 和 pLE 细胞中的 MAPK 和 PI3K/AKT 信号通路。

Cell Cycle Analysis

Cell Line: pTr and pLE cells
Concentration: 1, 2, 4 μM
Incubation Time: 48 h
Result: Increased G1 phase in pLE cells.
Decreased both G1 and S phases in pTr cells.
Reduced the ratio of cells in the G2/M phase by approximately 0.65- and 0.6-fold in pTr and pLE cells, respectively.
Increased the ratio of cells in the G1 phase by approximately 5.68- and 4.03-fold in pTr and pLE cells, respectively.

Cell Viability Assay

Cell Line: pTr and pLE cells
Concentration: 0.2, 0.5, 1, 2, 4, 5, 6 μM
Incubation Time: 48 h
Result: Decreased the viability of pTr cells (IC50 = 4.33 μM) and pLE cells (IC50 = 5.54 μM).

Apoptosis Analysis

Cell Line: pTr and pLE cells
Concentration: 1, 2, 4 μM
Incubation Time: 48 h
Result: Increased early apoptosis by 3.23 and 1.5 fold in pTr and pLE cells, respectively.
Increased late apoptosis by 3.1 and 1.73 fold in pTr and pLE cells, respectively.

Cell Migration Assay

Cell Line: pTr cells
Concentration: 4 μM
Incubation Time: 15 h
Result: Decreased the percentage of wound closure in pTr cells by 0.31 fold.

Real Time qPCR

Cell Line: pTr and pLE cells
Concentration: 4 μM
Incubation Time: 24 h
Result: Increased BAX by 1.31 fold, BAK1 by 1.3 fold, and CASP3 by 1.4 fold in pTr cells.
Increased BAX by 1.72 fold, BAK1 by 1.34 fold in pLE cells.
Increased the expression level of the cytochrome P450 enzyme-coding gene CYP1A1 in pTr cells.
Reduced the expression of FOLR1 and ITGAV, which are involved in implantation in pTr cells.

Western Blot Analysis

Cell Line: pTr and pLE cells
Concentration: 1, 2, 4 μM
Incubation Time: 3 h
Result: Increased the abundance of phosphorylated ERK1/2, JNK, and p38 and the expression levels of PI3K/AKT in pTr cells.
Increased the abundance of phosphorylated JNK and p38 in pLE cells.
Suppressed p-ERK1/2 levels by U0126 (MS-G35780) and Adezmapimod (SB203580) (MS-T90664) treatments in pTr and pLE cells.
Reduced p-JNK by SP600125 (MS-X95304), Wortmannin (MS-T11579) and U0126 in pTr and pLE cells.
Restored the levels of p-p38 and SP203580, whereas SP600125 increased the phosphorylation of p38 in pLE cells.
Down-regulated phospho-AKT levels following treatment with Wortmannin and SB203580, whereas only Wortmannin inhibited p-AKT in pLE cells.
Inhibited the phosphorylation of p70S6K by Wortmannin, U0126, and SB203580 in both cell lines.
Inhibited S6 by wortmannin and U0126 in pTr cells, whereas this target was significantly down-regulated by all four inhibitors in pLE cells.
体内研究
(In Vivo)

Picolinafen (0.1-100 μM,孵育,0-5 天) 在斑马鱼胚胎中 3 天时 LC50 为 10 μM,5 天时 LC50 为 5 μM。

Picolinafen (1-10 μM,孵育,24-72 h) 在斑马鱼胚胎发育过程中表现出毒性效应。

Animal Model: Zebrafish embryo
Dosage: 1, 5, 10 μM
Administration: Incubation for 24, 48 and 72 h
Result: Caused embryo hatching at 48 h, with “dead hatched embryos” observed and reduced “live embryos” to 30%, with only 22% surviving self-hatching at 10 μM at 72 h.
Impaired early embryogenesis evidenced by the larger eyes and brain, the smaller yolk sac and heart and a tail curvature reduction from 180° to 89° at 10 μM.
Increased the apoptotic cells localized in the eyes and tail region of zebrafish embryo.
Destroyed DNA and induced cell death especially in the eyes and yolk-sac of zebrafish embryos.
Reduced oxidative stress during embryogenesis at 5 μM.
Decreased the amount of angiogenesis in the trunk of zebrafish embryos at 5 μM.

化学信息

分子量 376.30
分子式 C19H12F4N2O2
CAS No. 137641-05-5
别名 氟吡酰草胺; AC 900001

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础